Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit. Issue 22 (15th November 2016)

• Record Type: Journal Article
• Authors: Wang, Min; Xu, Shan; Wu, Chunjiang; Liu, Xiaobo; Tao, Hong; Huang, Yanli; Liu, Yongchan; Zheng, Pengwu; Zhu, Wufu
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 26:Issue 22(2016)
• Page Start: 5450
• Page End: 5454
• Publication Date: 2016-11-15
• Subjects: Sorafenib derivatives -- (N-Methylpicolinamide-4-oxy) chalcones -- VEGFR-2/KDR kinase inhibitors -- Anticancer activity; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2016.10.029
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Two series of sorafenib derivatives ( N -methylpicolinamide-4-oxy) chalcones (5a –o, 7a –e ) were synthesized and characterized by NMR and MS. All of the target compounds were evaluated for the cytotoxicity against A549, HepG2, MCF-7, and PC-3 cancer cell lines and some selected compounds were further evaluated for the activity against VEGFR-2/KDR and BRAF kinases. The results indicated that all the compounds showed moderate to good antitumor activity, and the compound5c showed well cytotoxic activity against HepG2, MCF-7 and PC-3 cell lines with IC50 values of 0.56 ± 0.83 μM, 3.88 ± 1.03 μM and 3.15 ± 0.81 μM, which were 1.03–6.14-fold more active than sorafenib (3.44 ± 1.50 μM, 3.18 ± 1.43 μM, 3.24 ± 0.45 μM), respectively. The compound5b showed good activity on VEGFR-2/KDR kinase, and its IC50 value was 0.72 μM. Structure–activity relationships (SARs) and docking studies indicated that replacement of urea group of sorafenib by chalcone ketones improved the cytotoxic activity, and the results suggested that halogen [3-Br, 4-F] and methoxy (substituted on C-3, 4, 5 or C-2, 3, 4 position) substitution was benefit for the activity.